Astragalus 400 mg Explained: Immune Support, Stress, 5:1 Extract & What the Evidence Says

One capsule is 400 mg of a 5:1 root extract—not 400 mg of plain root. The licensed daily dose reaches a 4,000 mg dried-root equivalent, with precise immune and adaptogen claims.

QUICK ANSWER Biogenique Astragalus provides 400 mg of a 5:1 Astragalus membranaceus root extract per capsule, equivalent to 2,000 mg of dried root. The licensed adult dose—one capsule twice daily—therefore supplies 800 mg of extract, equivalent to 4,000 mg of dried root per day. The product is licensed to help maintain a healthy immune system and as an adaptogen for energy and resistance to stress-related mental or physical fatigue. It is not licensed to prevent infections, treat disease, act as a stimulant, or guarantee a standardized polysaccharide level.

What is Astragalus?

Astragalus membranaceus is a perennial plant whose root has a long history of use in Chinese medicine, where it is commonly known as Huang Qi. Modern supplements may contain powdered root, extracts made at different ratios, standardized fractions, injectable preparations used in clinical research, or multi-herb formulas. Those forms are not interchangeable. This Biogenique product contains an oral 5:1 extract of the root, and its claims must be read from its own Canadian product licence.

That distinction is especially important with astragalus because research headlines often travel much farther than the underlying study. An immune-cell marker, a fatigue score in a medically complex population, or an effect from an intravenous purified polysaccharide does not establish the same outcome for a retail root-extract capsule. The useful question is not simply “What has astragalus ever been studied for?” It is “What does this formula contain, what is it licensed to say, and how closely does the research match?”

What exactly is in the Biogenique formula?

Medicinal ingredient: Astragalus membranaceus root extract, 400 mg per capsule.
Extract ratio: 5:1, equivalent to 2,000 mg of dried astragalus root per capsule.
Licensed adult dose: one capsule, two times daily.
Daily total: 800 mg of extract, equivalent to 4,000 mg of dried root.
Bottle size: 60 capsules, equal to 30 days at the licensed dose; NPN 80132220.

The reviewed licence does not verify a particular polysaccharide percentage, a non-medicinal ingredient list, a vegetarian-capsule claim, or a finished-product contaminant result. Those may be documentable from other current records, but they should not be inferred from the medicinal-ingredient entry alone.

What does a 5:1 extract mean?

An extract ratio describes the relationship between the starting dried plant material and the resulting extract used in the capsule. At a 5:1 ratio, five parts of dried root are represented by one part of extract. For this formula, the label math is straightforward: 400 mg of extract × 5 = a 2,000 mg dried-root equivalent per capsule. At two capsules daily, 800 mg of extract × 5 = a 4,000 mg dried-root equivalent per day.

Step	Calculation	Result
Per capsule	400 mg extract × 5	2,000 mg dried-root equivalent
Licensed daily dose	2 capsules × 400 mg extract	800 mg extract daily
Daily herbal equivalent	800 mg extract × 5	4,000 mg dried-root equivalent

This is not a claim that the extract is “five times more powerful” in a clinical sense. It also does not prove a specific concentration of astragalosides or polysaccharides, because an extraction ratio is not the same as chemical standardization. And the numbers should not be written as 5,000:1 or as 2,000 mg of extract. The precise description is “400 mg of a 5:1 root extract, equivalent to 2,000 mg of dried root.”

Three evidence layers that should not be blended

Evidence layer	What can be said	What cannot be inferred
Licensed product claim	Helps maintain a healthy immune system; adaptogen that helps increase energy and resistance to stress, for example mental or physical fatigue related to stress.	No licensed claim to prevent colds, treat infection, cure fatigue, stimulate the body, or treat a disease.
Ingredient research	Human studies have examined immune biomarkers and fatigue in selected patient populations using varied astragalus forms and doses.	A result from another preparation, route, dose, population, or combination does not prove an effect for this capsule.
Quality documentation	The product licence verifies the medicinal ingredient, extract ratio, herbal equivalent, dose, purpose and required risk statements.	It does not prove better absorption, a standardized active level, “high potency,” or every-batch purity and potency.

What does the immune-support evidence show?

The licensed wording is maintenance-focused: astragalus may help maintain a healthy immune system. That is narrower than “boosts immunity,” which can suggest a stronger, faster or universally beneficial effect. It is also different from preventing colds, shortening infections, protecting against influenza, or treating an immune disorder. None of those outcomes appears on this product licence.

A 2023 systematic review and meta-analysis evaluated 19 human studies involving 1,094 participants and reported changes in several humoral and cellular immune measures, including selected cytokines and T-cell markers. The analysis also found substantial heterogeneity—meaning the participants, interventions, study methods and results varied considerably. These findings support continued research into immunologic activity, but they do not establish that this exact product reduces the number or duration of respiratory infections.

Immune biomarkers are intermediate measurements. A laboratory change may help explain a biological pathway, yet it does not automatically predict whether a person will feel better, avoid an illness or recover sooner. A responsible product article can state the licensed maintenance claim and describe the research context without turning a marker into a promised clinical outcome.

What does “adaptogen” mean here?

For this product, the licensed adaptogen claim is tied to helping increase energy and resistance to stress over time, such as mental or physical fatigue related to stress. The wording does not mean astragalus is a stimulant. The licence does not promise an immediate energy surge, caffeine-like alertness, improved athletic performance or treatment for persistent fatigue.

One randomized placebo-controlled trial studied oral Astragalus membranaceus in 64 people with post-stroke fatigue. Participants received 2.8 g three times daily—8.4 g per day—for 28 days. That medically specific population and regimen differ from this product’s 4 g dried-root equivalent per day. The trial is relevant to the research history of astragalus, but it cannot be used as product-specific proof for everyday stress-related tiredness.

A 2024 trial in 66 people receiving adjuvant chemotherapy for early breast cancer investigated intravenous, highly purified astragalus polysaccharides rather than an oral whole-root extract. The overall primary fatigue comparison was not statistically significant, although subgroup signals were reported. Route, composition, clinical context and endpoint all differ. It would be misleading to use that study to market this capsule as a treatment for cancer-related fatigue.

PRACTICAL INTERPRETATION The licence supports a gradual, stress-related adaptogen story—not a stimulant story. Take the product according to the label and evaluate it on that basis. New, severe, unexplained or persistent fatigue can have medical causes and should not be masked with a supplement claim.

Claims the current evidence does not establish for this product

Astragalus has been studied in cardiovascular, metabolic, kidney, oncology and ageing-related settings. Much of that literature involves disease-specific populations, combination therapies, varied extracts, purified fractions, injections, or outcomes that are not directly perceptible to consumers. The existence of such studies is not a licence to attach every researched topic to one retail capsule.

Prevention or treatment of colds, influenza, COVID-19 or other infections.
Treatment of cardiovascular, kidney, blood-sugar, autoimmune or cancer-related conditions.
Anti-ageing, telomere-lengthening, longevity or “cellular rejuvenation” outcomes.
A guaranteed high concentration of polysaccharides, astragalosides or other actives without a current specification and assay.
Better absorption, greater bioavailability, superior potency or faster results than another astragalus format.

The current product page also uses antioxidant language. Astragalus constituents can show antioxidant activity in laboratory or preclinical research, but antioxidant support is not an authorized claim on NPN 80132220. If that benefit is commercially important, it should be supported through the appropriate licensing and evidence process rather than added by association.

How to take this exact product

The licensed direction is for adults 18 years and older: take one capsule two times daily. That provides the 4,000 mg dried-root equivalent daily dose described above. Health Canada’s current Astragalus membranaceus monograph lists 2–4.8 g of dried root per day for the immune-maintenance and adaptogen purposes, placing this product’s 4 g daily equivalent within that monograph range.

The product licence does not require taking the capsules with food, does not set a morning-versus-evening schedule and does not state a maximum duration of use. Those absences should not be filled with invented rules. Choose a consistent schedule that fits the label, and consult a health-care practitioner if personal conditions or medications make timing important. Doses from trials should not replace the licensed directions.

Safety, cautions and contraindications

The product licence directs users to consult a health-care practitioner before use if they are pregnant or breastfeeding, or if they have an autoimmune disorder. The U.S. National Center for Complementary and Integrative Health also notes a potential concern with medicines that suppress the immune system. People using transplant, autoimmune-disease or other immunosuppressive therapies should discuss astragalus with their care team rather than self-prescribing it.

The licence also carries traditional Chinese medicine contraindications. Do not use in cases of exterior excess, qi stagnation, damp obstruction, food stagnation, yin deficiency with heat signs, or during the early stages of skin lesions or when there is a heat toxin. These are specialized TCM concepts; someone using astragalus within a traditional treatment framework should seek guidance from a qualified practitioner.

NCCIH reports that oral astragalus may be safe for many adults but has not been thoroughly evaluated, and reliable information in pregnancy and breastfeeding is limited. Safety cannot be assumed from “natural” status. Stop use and seek appropriate advice for a suspected adverse reaction, and obtain urgent care for signs of a severe allergic reaction.

The quality question the website cannot answer alone

The reviewed product licence verifies the medicinal ingredient, extract ratio, equivalent quantity, dose, purpose and risk statements. No current, finished-product, lot-specific certificate of analysis for Biogenique Astragalus was located in the reviewed files. That means the available records do not independently confirm the current lot’s identity, assay, microbiological results, heavy metals or other relevant contaminants.

The Health Canada issuance letter is also explicit that the finished-product specifications and mock labels were not reviewed for accuracy as part of the licence decision, and that the licensee must hold evidence for marketing terms. Therefore, statements such as “every batch is tested for purity and potency,” “high concentration of active polysaccharides,” “better absorption,” “non-GMO,” or broad allergen-free claims need current supporting documentation before publication.

A useful COA should match the product, lot number and expiry and report applicable specifications, methods and results—not just display a generic pass statement. Until that record is available, the article should distinguish verified licence facts from quality claims that remain pending.

Frequently asked questions

Is it 400 mg or 2,000 mg per capsule?

Both numbers describe different parts of the same formula. Each capsule contains 400 mg of a 5:1 extract. That extract is equivalent to 2,000 mg of dried root. The most accurate short description includes both numbers so readers do not confuse extract mass with herbal equivalent.

Does astragalus prevent colds?

This product is licensed to help maintain a healthy immune system, not to prevent or treat colds. Human immune-marker research is not the same as demonstrating fewer infections. Avoid turning the maintenance claim into a guarantee that a user will not get sick.

Is astragalus a stimulant?

No stimulant claim appears on the licence. Its adaptogen wording relates to helping increase energy and resistance to stress over time, including mental or physical fatigue related to stress. It should not be described as a caffeine replacement or an instant energy product.

Can I use it with an autoimmune disorder?

The licence says to consult a health-care practitioner before use if you have an autoimmune disorder. Because immune-active products may also be relevant to immunosuppressive treatment, obtain individualized advice from the clinician managing the condition and medications.

How long can I take it?

The licence does not specify a maximum duration. That does not mean indefinite use is automatically appropriate for everyone. Follow the current label and reassess the need, response, medications and health circumstances with a qualified practitioner when appropriate.

The bottom line

Biogenique Astragalus has a useful, precise story: 400 mg of a 5:1 Astragalus membranaceus root extract per capsule, equivalent to 2,000 mg of dried root; one capsule twice daily; and licensed purposes for immune-system maintenance and adaptogenic support for energy and resistance to stress-related fatigue. The daily 4 g dried-root equivalent fits Health Canada’s current monograph range for those purposes.

The evidence boundary matters just as much as the benefit. Immune biomarkers do not prove fewer infections, trials in post-stroke or chemotherapy-related fatigue do not prove routine consumer outcomes, and an extract ratio does not prove standardized actives or superior absorption. Keep the copy trustworthy by using the licensed language, showing the extract math, retaining all cautions, and obtaining a current lot-specific COA before publishing broad quality claims.

PUBLICATION GATE Retain the licensed immune-maintenance and stress-related adaptogen wording. Correct “400 mg root” to “400 mg of a 5:1 root extract, equivalent to 2,000 mg dried root.” Remove or qualify antioxidant, infection-prevention, heart, glucose, kidney, anti-ageing, telomere, standardized-polysaccharide, better-absorption, high-potency and every-batch claims. Surface the twice-daily dose, pregnancy/breastfeeding and autoimmune cautions, and the traditional Chinese medicine contraindications. Obtain a current product- and lot-specific COA before making quality claims.

Product link

View Biogenique Astragalus

Sources

Educational information only; not medical advice. Natural health product claims, directions and risk statements are product- and licence-specific. Always read the current label.